Jun 24, 2025 8:00am EDT Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Jun 04, 2025 8:00am EDT Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Apr 24, 2025 4:15pm EDT Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Apr 23, 2025 4:41pm EDT Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Apr 23, 2025 8:00am EDT Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Apr 15, 2025 8:00am EDT Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Mar 31, 2025 8:00am EDT Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules